Jose Esquilin
Pediatric Hematology-Oncology · Corpus Christi, TXNPI 1417131350
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,388 of the $23,286 with a category attached, or 66.1%. Global Blood Therapeutics, Inc. accounts for 66.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2020 at $8,044 and has fallen 88.1% since, to $961 in 2025. Among pediatric hematology-oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $133.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$15K
- Jazz Pharmaceuticals Inc.$2K
- AstraZeneca$752
- Servier Pharmaceuticals LLC$733
- Fennec Pharmaceuticals, Inc.$676
- Sobi, Inc$665
- plus $3K from 28 others
Across 16 payments — averaging $21,516 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$322K
- Merck$21K
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$15,38866%
- Food & beverage$7,59933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 16 | $15,366 |
| Jazz Pharmaceuticals Inc. | 46 | $2,200 |
| AstraZeneca(2 entities) | 13 | $752 |
| Servier Pharmaceuticals LLC | 7 | $733 |
| Fennec Pharmaceuticals, Inc. | 7 | $676 |
| Sobi, Inc | 7 | $665 |
| Novartis | 18 | $414 |
| BTG International Inc. | 4 | $342 |
| Pfizer | 9 | $252 |
| Sanofi-aventis U.S. LLC | 2 | $184 |
| Y-mabs Therapeutics, Inc. | 3 | $167 |
| Amgen(2 entities) | 2 | $141 |
| Novo Nordisk | 2 | $137 |
| Adaptive Biotechnologies Corporation | 1 | $128 |
| Agios Pharmaceuticals, Inc. | 1 | $126 |
| RARE Disease Therapeutics, Inc. | 1 | $115 |
| Bioverativ Therapeutics Inc. | 1 | $109 |
| United Therapeutics Corporation | 1 | $93 |
| AbbVie | 5 | $91 |
| QOL Medical, LLC | 3 | $88 |
| Pharming Healthcare, Inc. | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Alcresta Therapeutics, Inc. | 2 | $53 |
| Nestle Healthcare Nutrition Inc. | 2 | $49 |
| Cumberland Pharmaceuticals, Inc. | 3 | $39 |
| Mirum Pharmaceuticals, Inc. | 2 | $37 |
| Bayer | 1 | $29 |
| Emmaus Medical, Inc. | 1 | $26 |
| Duchesnay USA Incorporated | 1 | $24 |
| Day One Biopharmaceuticals | 1 | $22 |
| Travere Therapeutics, Inc. | 2 | $19 |
| Sandoz | 1 | $17 |
| USWM, LLC | 1 | $16 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,286 in reported general payments places this provider in the 90th percentile of 235 pediatric hematology-oncology providers in Texas.
Other pediatric hematology-oncology in Corpus Christi
- Stanton GoldmanDallas$234K
- Vivek SubbiahHouston$194K
- Maurizio GhisoliDallas$174K
- Anish RayFort Worth$164K
- Joel WeinthalDallas$161K
- Prasad MathewEl Paso$153K
- Vinod Gidvani-DiazSan Antonio$101K
- Kelly VallanceFort Worth$82K
- Scott PenneySan Antonio$75K
- Ayesha ZiaDallas$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.